title: Val66Met polymorphism and serum brain-derived neurotrophic factor in bipolar disorder: an open-label trial.
abstract: OBJECTIVE
  Brain-derived neurotrophic factor (BDNF) is consistently associated with acute mood episodes in bipolar disorder, but there is a lack of longitudinal data to support this hypothesis. In this 16-week open-label clinical trial, we tested the predictive role of BDNF Val66Met polymorphism on serum BDNF levels and the relationship of serum BDNF and clinical response in people with bipolar disorder during an acute illness episode.
  
  
  METHODS
  Sixty-four people with bipolar disorder who were medication-free at baseline and in an acute mood episode were recruited. They were matched with 64 healthy controls. Clinical evaluation, serum BDNF, and BDNF Val66Met polymorphism were determined at baseline, and change in serum BDNF was assessed in patients at weeks 2, 4, 8 and 16.
  
  
  RESULTS
  There were no differences between patients and controls in serum BDNF or in frequencies of the BDNF Val66Met polymorphism genotype at baseline. The multivariable model showed that Met carriers had a significantly different change in BDNF levels compared with Val homozygotes. Not achieving a complete remission was also associated with lower prospectively assessed BDNF levels.
  
  
  CONCLUSIONS
  This study provides the first longitudinal evidence that both the BDNF Val66Met polymorphism and remission status predict change in circulating BDNF levels.
authors: Bipolar Disorders Unit, IDIBAPS, CIBERSAM, Clinical Institute of Neurosciences, Hospital Clínic, University of Barcelona, Barcelona, Spain.
authors: I
authors: I
authors: Grande
authors: P V S
authors: PV
authors: Magalhães
authors: I
authors: I
authors: Chendo
authors: L
authors: L
authors: Stertz
authors: G R
authors: GR
authors: Fries
authors: K M
authors: KM
authors: Cereser
authors: Â B M
authors: ÂB
authors: Cunha
authors: P
authors: P
authors: Gói
authors: M
authors: M
authors: Kunz
authors: M
authors: M
authors: Udina
authors: R
authors: R
authors: Martín-Santos
authors: B N
authors: BN
authors: Frey
authors: E
authors: E
authors: Vieta
authors: F
authors: F
authors: Kapczinski
mesh_terms: D000328:Adult; D000339:Affect / Q000502:physiology; D000342:Affective Symptoms / Q000097:blood / Q000175:diagnosis / Q000235:genetics; D019943:Amino Acid Substitution / Q000235:genetics; D015415:Biomarkers / Q000097:blood; D001714:Bipolar Disorder / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics / Q000523:psychology; D019208:Brain-Derived Neurotrophic Factor / Q000097:blood / Q000235:genetics; D001938:Brazil; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008715:Methionine / Q000235:genetics; D009473:Neuronal Plasticity; D062072:Patient Acuity; D011110:Polymorphism, Genetic; D011569:Psychiatric Status Rating Scales; D011619:Psychotropic Drugs / Q000494:pharmacology*; D014633:Valine / Q000235:genetics
chemical_list: D015415:Biomarkers; D019208:Brain-Derived Neurotrophic Factor; D011619:Psychotropic Drugs; C579455:BDNF protein, human; D008715:Methionine; D014633:Valine
keywords: biomarkers; bipolar disorder; brain-derived neurotrophic factor; quetiapine; treatment response